Closing arguments in LabMD case revolve around whether FTC met its burden
The following article first appeared on Sept. 17 on MLex. For more information on MLex, including getting access to its exclusive content, please contact email@example.com.
Much of the more than three...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch